- Home
- RIGL vs CYRX Comparison
RIGL vs CYRX Comparison
Compare RIGL & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | CYRX |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 883.3M |
| IPO Year | 2000 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RIGL | CYRX |
|---|---|---|
| Price | $48.73 | $17.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $63.00 | $19.78 |
| AVG Volume (30 Days) | 187.8K | ★ 638.0K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | 156.22 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | $176,177,000.00 |
| Revenue This Year | $3.89 | $10.96 |
| Revenue Next Year | $21.95 | $10.10 |
| P/E Ratio | $37.03 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $7.61 |
| 52 Week High | $52.24 | $18.67 |
Technical Indicators
Market Signals| Indicator | RIGL | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 57.25 |
| Support Level | $44.50 | $14.55 |
| Resistance Level | $50.19 | $18.17 |
| Average True Range (ATR) | 1.83 | 0.74 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 66.42 | 65.76 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.